Work

Phase 1 study of sorafenib and irinotecan in pediatric patients with relapsed or refractory solid tumors.

Year: 2014

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2014.32.15_suppl.10052

Authors: Holly Jane Meany, Jeffrey Dome, Pamela S. Hinds, Rochelle Bagatell, Suzanne Shusterman, Brigitte C. Widemann, Emily Stern, Wendy B. London, AeRang Kim, Elizabeth Fox, Carlos Rodriguez-Galindo, Jane E. Minturn

Institutions: Children's National, Children's Hospital of Philadelphia, Dana-Farber Cancer Institute, National Institutes of Health, National Cancer Institute, Boston Children's Hospital, Dana-Farber/Boston Children's Cancer and Blood Disorders Center

Language: English

Topic: Cancer therapeutics and mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2908019308

Cites:

Cited by: 2

Related to: 10